Allogenica
Created in 2022
Up & running (A)
Existing signals show a regular activitySocial networks
2,114Activities
Technologies
Entity types
Location
Adenine, Av. Rockefeller, 69008 Lyon, France
Lyon
France
Employees
Scale: 2-10
Estimated: 8
SIREN
909634958Engaged catalyst
17
0 0Added in Motherbase
10 months ago
Value proposition
"Designs the immunotherapy of tomorrow"
At Allogenica, we are transforming cell therapies for a healthier tomorrow.
Our mission is to disrupt the treatment landscape for cancer, rare diseases, and autoimmune disorders.
We're developing a breakthrough cell therapy platform with the potential to:
• Replace transplants: Providing less invasive, accessible alternatives for thousands of patients who currently have limited treatment options.
• Expand access for all: With predictable safety and efficacy, we aim to make cell therapies available to a a broader patient population.
• Dramatically reduce costs: By streamlining production, we aim to significantly lower the cost of cell therapies, making transformative treatments more accessible globally.
Leading Cell Therapy Revolution
Founded in 2022, Allogenica has rapidly emerged as a pioneer in the field. Our innovative approach includes:
• Proprietary Pre-T Cell Therapies: Enhancing compatibility with patients' immune systems, reducing the risk of rejection.
• Scalable, Broad Applications: Our platform has the potential to treat a diverse range of diseases, ensuring scalability and reaching more patients in need.
• Cost-Effective, Rapid Solutions: Delivering affordable and faster-to-market therapies, to change lives on a global scale, potentially impacting millions.
Allogenica is a preclinical-stage biotechnology company headquartered in Lyon, France.
Join us in transforming the future of healthcare!
#CellTherapy #Biotech #HealthcareInnovation #CancerTreatment #RareDiseases #AutoimmuneDisorders #Lyon
Biotechnology, AutoimmuneDisorders, #CellTherapy, Biotech , CancerTreatment, RareDiseases, and HealthcareInnovationOriginal language
"Designs the immunotherapy of tomorrow"
At Allogenica, we are transforming cell therapies for a healthier tomorrow.
Our mission is to disrupt the treatment landscape for cancer, rare diseases, and autoimmune disorders.
We're developing a breakthrough cell therapy platform with the potential to:
• Replace transplants: Providing less invasive, accessible alternatives for thousands of patients who currently have limited treatment options.
• Expand access for all: With predictable safety and efficacy, we aim to make cell therapies available to a a broader patient population.
• Dramatically reduce costs: By streamlining production, we aim to significantly lower the cost of cell therapies, making transformative treatments more accessible globally.
Leading Cell Therapy Revolution
Founded in 2022, Allogenica has rapidly emerged as a pioneer in the field. Our innovative approach includes:
• Proprietary Pre-T Cell Therapies: Enhancing compatibility with patients' immune systems, reducing the risk of rejection.
• Scalable, Broad Applications: Our platform has the potential to treat a diverse range of diseases, ensuring scalability and reaching more patients in need.
• Cost-Effective, Rapid Solutions: Delivering affordable and faster-to-market therapies, to change lives on a global scale, potentially impacting millions.
Allogenica is a preclinical-stage biotechnology company headquartered in Lyon, France.
Join us in transforming the future of healthcare!
#CellTherapy #Biotech #HealthcareInnovation #CancerTreatment #RareDiseases #AutoimmuneDisorders #Lyon
Allogenica | Future-ready Cell Therapy
We are committed to making T-cell therapies universally accessible by delivering treatments that are safer, more readily available to patients, and up to ten times less expensive to manufacture.
https://www.allogenica.com/
| Catalyst | Type | Tweets | Articles | |
|---|---|---|---|---|
 ANSSI - Agence nationale de la sécurité des systèmes d'information Computer and Network Security | ANSSI - Agence nationale de la sécurité des systèmes d'information Computer and Network Security | Other 9 Apr 2025 | | |
 Gouvernement Government Administration | Gouvernement Government Administration | Other 9 Apr 2025 | | |
 Ministère des Affaires étrangères français Public Policy Offices | Ministère des Affaires étrangères français Public Policy Offices | Other 9 Apr 2025 | | |
 Ministère de la Culture Public Policy Offices | Ministère de la Culture Public Policy Offices | Other 9 Apr 2025 | | |
 Ministère de la Défense Government Administration | Ministère de la Défense Government Administration | Other 9 Apr 2025 | | |
 Ministère de l'Enseignement supérieur, de la Recherche et de l'Espace Government Administration | Ministère de l'Enseignement supérieur, de la Recherche et de l'Espace Government Administration | Other 9 Apr 2025 | | |
 Ministère de l'Agriculture et de la Souveraineté alimentaire Government Administration | Ministère de l'Agriculture et de la Souveraineté alimentaire Government Administration | Other 9 Apr 2025 | | |
 Ministry of Economy Government Administration | Ministry of Economy Government Administration | Other 9 Apr 2025 | | |
 PULSALYS Research, Research Services | PULSALYS Research, Research Services | Other 9 Apr 2025 | | |
 MEDICALPS Business Consulting and Services | MEDICALPS Business Consulting and Services | Other 22 Jan 2024 | | |